The regulatory approval of the Investigational New Drug application for SI-B037 represents the first time the company has utilized New Approach Methodologies (NAMs) as the primary basis for its safety assessment. By prioritizing human-centric models, SystImmune aims to gain a more precise understanding of how the molecule interacts with complex human pathways, a task often obscured by conventional animal testing.
In section Releases
SystImmune Clears FDA Hurdle With Animal-Free Testing for SI-B037
Redmond-based SystImmune has secured FDA clearance for its bispecific antibody SI-B037, marking a pivotal shift in pharmaceutical development. The company bypasses traditional animal toxicology studies, relying instead on human organ-on-chip systems and primary tissue models to satisfy safety requirements for its upcoming Phase 1/1b clinical trials.
Dr. Jahan Khalili, Senior Vice President of Research, noted that these human-relevant models provide a direct read on the drug's mechanism, which is designed to address immunosuppression in patients with advanced solid tumors. As the company prepares for initial human trials, Dr. Anand Achanta, Senior Vice President of Regulatory Affairs, emphasized the urgent need for new therapies for those who have failed to respond to standard treatments. The upcoming Phase 1/1b study will serve as a critical test for both the efficacy of the drug and the reliability of these modern, non-animal testing alternatives in clinical development.
Comments (0)
No comments yet. Be the first!